Enzyme May Help Doctors Determine Mesothelioma Prognosis
Cancer researchers in New York say they have found a new way to help determine prognosis for people with malignant pleural mesothelioma. In a report in the Annals of Surgical Oncology, a team of doctors from Memorial Sloan Kettering Cancer Center say patients whose cancer cells tested positive for an enzyme called CD10 had more aggressive mesothelioma and shorter survival times. Right now, stage (a measure of how far cancer has spread in the body) and type are the primary prognostic factors for mesothelioma. People with more advanced cancer or non-epithelioid mesothelioma tend to have poorer outcomes than people with epithelioid or early-stage mesothelioma. By offering another reliable prognostic factor, the new study suggests that CD10 can help make the process more effective, which may improve…